People: Gilead Sciences Inc (GILD.O)

Summary

Name	Age	Since	Current Position
John Martin	61	2008	Chairman of the Board, Chief Executive Officer
John Milligan	52	2008	President, Chief Operating Officer
Robin Washington	50	2008	Chief Financial Officer, Senior Vice President
Norbert Bischofberger	57	2007	Executive Vice President - Research and Development, Chief Scientific Officer
Gregg Alton	47	2009	Executive Vice President - Corporate and Medical Affairs
Kevin Young	55	2004	Executive Vice President - Commercial Operations
Per Wold-Olsen	65	2010	Director
John Cogan	65	2005	Independent Director
Etienne Davignon	80	1990	Independent Director
Carla Hills	79	2007	Independent Director
Kevin Lofton	58	2009	Independent Director
John Madigan	75	2005	Independent Director
Nicholas Moore	71	2004	Independent Director
Richard Whitley	67	2008	Independent Director
Gayle Wilson	70	2001	Independent Director
Patrick O'Brien			Investor Relations

» Insider Trading

Biographies

Name	Description
John Martin	Dr. John C. Martin, Ph.D., is Chairman of the Board, Chief Executive Officer of Gilead Sciences Inc. He was appointed as Chairman of Gilead’s Board in May 2008 and has served as Gilead’s Chief Executive Officer and a member of Gilead’s Board of Directors since April 1996. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb Company and Syntex Corporation. He is a member of the Board of Directors of the California Healthcare Institute and Gen-Probe Incorporated. He also serves on the University of Southern California Board of Trustees. Dr. Martin previously served as President of the International Society for Antiviral Research, Chairman of the Board of Directors of BayBio and Chairman of the Board of Directors of the California Healthcare Institute. He served on the National Institute of Allergy and Infectious Diseases Council, the Board of Directors of the Biotechnology Industry Organization, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the external scientific advisory board of the University of California School of Global Health. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. Dr. Martin holds a PhD in organic chemistry from the University of Chicago and an MBA in marketing from Golden Gate University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies.
John Milligan	Dr. John F. Milligan, Ph.D., is President, Chief Operating Officer of Gilead Sciences Inc. Dr. Milligan joined Gilead in 1990 as a Research Scientist, and in 1996, he became Director of Project Management and Project Team Leader for Gilead’s collaboration with Hoffmann-La Roche Ltd on Tamiflu®. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was promoted to Chief Operating Officer in 2007 and President in 2008. Dr. Milligan is a member of the board of Biotechnology Industry Organization (BIO), and a trustee of Ohio Wesleyan University. Dr. Milligan received his B.A. in chemistry from Ohio Wesleyan University and his Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
Robin Washington	Ms. Robin L. Washington is Chief Financial Officer, Senior Vice President of Gilead Sciences, Inc. Ms. Washington joined the company in May 2008. Prior to joining Gilead, Ms. Washington served as Chief Financial Officer of Hyperion Solutions, an enterprise software company that was acquired by Oracle Corporation in March 2007. Ms. Washington also spent nearly 10 years at PeopleSoft, a provider of enterprise application software, most recently in the role of Senior Vice President and Corporate Controller. She previously was a Director of Finance for Tandem Computers, an Accounting Analyst for the Federal Reserve Bank of Chicago and a Senior Auditor for Deloitte & Touche. Ms. Washington holds a bachelor’s degree in business administration from the University of Michigan and an MBA from Pepperdine University. She currently serves on the board of directors of MIPS Technologies, Inc. and previously served on the board of directors of Tektronix, Inc.
Norbert Bischofberger	Dr. Norbert W. Bischofberger, Ph.D., is Executive Vice President - Research and Development, Chief Scientific Officer of Gilead Sciences Inc. Dr. Bischofberger joined the Company in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining the Company, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.’s DNA Synthesis group from 1986 to 1990. He received his B.S. in Chemistry at the University of Innsbruck in Austria and his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule (ETH) in Zurich, Switzerland and performed postdoctoral work at Harvard University.
Gregg Alton	Mr. Gregg H. Alton is Executive Vice President - Corporate and Medical Affairs of Gilead Sciences Inc. Mr. Alton joined the company in 1999, and served as General Counsel from 2000 to 2009. In his current role, Mr. Alton is responsible for legal affairs, corporate compliance and quality, government affairs, medical affairs, public affairs and international access activities. Prior to joining the company , Mr. Alton was an attorney at the law firm of Cooley Godward Kronish LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board of the AIDS Healthcare Foundation, a member of the board of Oculus Innovative Sciences, Inc. and a member of the board of BayBio, a San Francisco Bay Area life sciences industry organization. He received his B.A. in Legal Studies from the University of California at Berkeley and his J.D. from Stanford University.
Kevin Young	Mr. Kevin Young, CBE, is Executive Vice President - Commercial Operations of Gilead Sciences, Inc. Mr. Young joined the company in September 2004. Mr. Young is a 28-year veteran of the biopharmaceutical industry, with a career that spans a variety of therapeutic categories including cardiology, oncology, rheumatology, hepatitis and HIV/AIDS. He previously held positions at Amgen, Inc. and AstraZeneca Pharmaceuticals (formerly ICI Pharmaceuticals). During his 12 years at Amgen, Mr. Young held a number of positions in Europe and the United States, most recently as Head of the U.S. Inflammation Business Unit the re-launch of Enbrel® following the acquisition of Immunex Corporation. In 2011, Mr. Young was appointed Commander of The British Empire, one of Great Britain’s highest civilian honors, in recognition of his service to the healthcare and pharmaceutical industries. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool John Moores University and Nottingham University in England and has completed the Executive Program at the University of Michigan.
Per Wold-Olsen	Mr. Per Wold-Olsen is Director of Gilead Sciences Inc. After serving as the Chair of Health Policy Advisory Board since 2007. From 2005 to 2006, he served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S. He also serves as a director of Exiqon A/S and Novo A/S. Mr. Wold-Olsen is a member of the Board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria. Mr. Wold-Olsen previously served as a director of PharmaNet Development Group, Inc.
John Cogan	Dr. John F. Cogan, Jr., is Independent Director of Gilead Sciences Inc. Dr. Cogan is currently the Leonard and Shirley Ely Senior Fellow at the Hoover Institution and a Professor in the Public Policy Program at Stanford University, where he has had a continuing appointment since 1980. Dr. Cogan’s current research is focused on U.S. budget and fiscal policy, social security and healthcare. Dr. Cogan has held a number of positions in the U.S. government, including Assistant Secretary for Policy in the U.S. Department of Labor and Associate Director and Deputy Director in the U.S. Office of Management and Budget. Dr. Cogan is a trustee of the Charles Schwab Family of Funds and a director of Venture Lending and Leasing Funds II, IV and VI, Inc.
Etienne Davignon	Viscount Etienne F. Davignon is Independent Director of Gilead Sciences Inc. He is currently Minister of State and serves as Chairman of Recticel, CMB, SN Air Holding and Genfina and as a director of Sofina. Previously, he served as Vice Chairman of Suez-Tractebel and Chairman of Société Générale de Belgique. Mr. Davignon has served as the European Community’s Commissioner for Industry and International Markets and as the European Community’s Vice President for Research, Industry and Energy Policies.
Carla Hills	Ambassador Carla A. Hills is Independent Director of Gilead Sciences Inc. Since 1993, she has served as the Chair and Chief Executive Officer of Hills & Company, a firm providing advice to U.S. businesses on investment, trade and risk assessment issues outside the United States. Mrs. Hills served as U.S. Trade Representative from 1989 to 1993, and was principal advisor on international trade to President George H. W. Bush. Under President Gerald R. Ford, she served as Secretary of Housing and Urban Development. Mrs. Hills is a director of TCW Group, Inc. and serves on the international advisory boards of J.P. Morgan Chase, Rolls Royce and the Coca-Cola Company. Mrs. Hills previously served as a director of American International Group, Inc., Chevron Corporation and Time Warner, Inc. She is also Chair of the National Committee on U.S.-China Relations and Co-Chair of the Inter-American Dialogue, the Council on Foreign Relations and the International Advisory Board of the Center for Strategic and International Studies. She is also a member of the Executive Committee of the Peterson Institute for International Economics and of the Trilateral Commission, and a member of the board of the International Crisis Group.
Kevin Lofton	Mr. Kevin E. Lofton is Independent Director of Gilead Sciences, Inc. He is currently the President and Chief Executive Officer of Catholic Health Initiatives, a Denver-based healthcare system operating the full continuum of services from hospitals to home health agencies throughout the nation. He previously served as Chief Executive Officer of two university hospitals, the University of Alabama at Birmingham Hospital and Howard University Hospital in Washington, D.C. In 2007, Mr. Lofton served as Chairman of the Board of the American Hospital Association. Mr. Lofton also serves on the Board of Directors of the Morehouse School of Medicine, Atlanta, and the Georgia State University J. Mack Robinson College of Business, also in Atlanta.
John Madigan	Mr. John W. Madigan is Independent Director of Gilead Sciences Inc. He is the retired Chairman and Chief Executive Officer of Tribune Company, a media company, operating businesses in broadcasting, publishing and on the Internet. He is also a director and former Chairman of the Robert R. McCormick Foundation and a director of Boise Cascade Holdings, L.L.C. Mr. Madigan is a former director of Morgan Stanley, a former member of the Defense Business Board of the Department of Defense, an advisor to Madison Dearborn Partners and a director and former Chairman of The Chicago Council on Global Affairs. He also serves as a trustee of Northwestern University, Rush University Medical Center and the Paley Center for Media in New York. Mr. Madigan is a member and former Chairman of The Commercial Club of Chicago and a director of New Schools for Chicago.
Nicholas Moore	Mr. Nicholas G. Moore is Independent Director of Gilead Sciences Inc. Mr. Moore is the retired global Chairman of PricewaterhouseCoopers LLP, a professional services firm formed in July 1998 by the merger of Coopers & Lybrand and Price Waterhouse. Prior to the merger, Mr. Moore was elected Chairman and Chief Executive Officer of Coopers & Lybrand (U.S.) in 1994 and Coopers & Lybrand International in 1997. Mr. Moore is the lead independent director of NetApp, Inc. and a director of Bechtel Group, Inc., Wells Fargo, Inc. and one private venture capital-backed technology company. He has also served as Chairman of the Board of Trustees of St. Mary’s College of California. Mr. Moore is an inactive member of the American Institute of Certified Public Accountants, the California Bar Association, and the California and New York Society of Certified Public Accountants.
Richard Whitley	Dr. Richard James Whitley, M.D., is Independent Director of Gilead Sciences Inc. He also serves as the Distinguished Professor, Loeb Scholar Chair in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the University of Alabama at Birmingham. Dr. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a former President of the International Society of Antiviral Research, chairs the Board of Scientific Councilors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention and is President of the Board of the Infectious Disease Society of America.
Gayle Wilson	Mrs. Gayle E. Wilson is Independent Director of Gilead Sciences Inc. Mrs. Wilson served as California’s First Lady from 1991 to 1999. Mrs. Wilson is Chairman of the board of directors of the Ralph M. Parsons Foundation, a non-profit organization that provides higher education, social impact, civic and cultural issues and health grants. She is also the Chair Emeritus of the Advisory Board of the California State Summer School for Math and Science, a member of the board of trustees of the California Institute of Technology and a member of the board of the Society for Science and the Public and the Sanford Burnham Institute for Medical Research.
Patrick O'Brien

Basic Compensation

Name	Fiscal Year Total
John Martin	15,257,300
John Milligan	7,028,700
Robin Washington	4,175,590
Norbert Bischofberger	5,397,890
Gregg Alton	4,035,530
Kevin Young	4,564,250
Per Wold-Olsen	--
John Cogan	--
Etienne Davignon	--
Carla Hills	--
Kevin Lofton	--
John Madigan	--
Nicholas Moore	--
Richard Whitley	--
Gayle Wilson	--
Patrick O'Brien	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
John Martin	8,255,948	264,510,804
John Milligan	1,917,420	53,086,100
Robin Washington	382,650	2,922,500
Norbert Bischofberger	1,885,000	59,342,600
Gregg Alton	121,025	3,274,660
Kevin Young	1,296,492	28,934,850
Per Wold-Olsen	0	0
John Cogan	0	0
Etienne Davignon	0	0
Carla Hills	0	0
Kevin Lofton	0	0
John Madigan	0	0
Nicholas Moore	0	0
Richard Whitley	0	0
Gayle Wilson	0	0
Patrick O'Brien	0	0

Insider Trading

Name	Shares Traded	Price
MADIGAN JOHN W	5,852	$0.00
HILLS CARLA ANDERSON	5,852	$0.00
DAVIGNON ETIENNE F	5,852	$0.00
DAVIGNON ETIENNE F	1,756	$52.88
WOLD OLSEN PER	5,852	$0.00
COGAN JOHN F	5,852	$0.00
WILSON GAYLE E	5,852	$0.00
WHITLEY RICHARD JAMES	5,852	$0.00
LOFTON KEVIN E	5,852	$0.00
ALTON GREGG H	30,000	$50.20
MARTIN JOHN C	282,242	$7.63
MARTIN JOHN C	282,242	$50.17
ALTON GREGG H	26,000	$16.40
WASHINGTON ROBIN L	968	$50.20
WASHINGTON ROBIN L	3,000	$24.91
ALTON GREGG H	26,000	$16.40
ALTON GREGG H	29,500	$48.36
MARTIN JOHN C	101,000	$48.01
MARTIN JOHN C	181,242	$48.47
MARTIN JOHN C	282,242	$7.63
ALTON GREGG H	500	$48.97
WASHINGTON ROBIN L	10,000	$48.42
WASHINGTON ROBIN L	10,000	$27.07
WASHINGTON ROBIN L	3,000	$48.03
WASHINGTON ROBIN L	45,000	$27.07

» Full list on Insider Trading

People: Gilead Sciences Inc (GILD.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: